enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,741 shares, a decrease of 51.5% from the February 26th total of 7,709 shares. Based on an average trading volume of 2,988 shares, the days-to-cover ratio is currently 1.3 days.

enGene Price Performance

ENGNW stock remained flat at $2.31 during trading on Thursday. The company had a trading volume of 4,000 shares, compared to its average volume of 18,761. The firm’s 50-day moving average price is $3.02 and its 200-day moving average price is $2.39. enGene has a 12-month low of $0.51 and a 12-month high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.